Literature DB >> 29057029

Transthyretin Cardiac Amyloidosis in Older Adults: Optimizing Cardiac Imaging to the Corresponding Diagnostic and Management Goal.

Adam Castaño1, Daniel K Manson2, Mathew S Maurer2, Sabahat Bokhari3.   

Abstract

PURPOSE OF REVIEW: Transthyretin cardiac amyloidosis is increasingly recognized as an important cause of heart failure in older adults. Many cardiac imaging modalities have evolved to evaluate transthyretin cardiac amyloidosis and include 2D echocardiography with tissue Doppler and speckle-strain imaging, nuclear scintigraphy, cardiac magnetic resonance imaging, and positron emission tomography. The purpose of this review is to highlight the optimal selection of advanced cardiac imaging techniques with corresponding diagnostic goals including raising suspicion, making an early diagnosis, and subtyping transthyretin cardiac amyloid, as well as management goals including assessment of ventricular impairment, prognosticating, and monitoring disease progression. Potential benefits of optimizing cardiac imaging in the elderly patient with transthyretin cardiac amyloidosis may include enhanced and earlier diagnosis and refined long-term management. RECENT
FINDINGS: Advances in cardiac imaging techniques are changing diagnostic and management algorithms for transthyretin cardiac amyloidosis.
SUMMARY: With a new era of novel therapeutics, enhanced recognition, and earlier diagnosis approaching, selecting the appropriate non-invasive cardiac imaging modality will be essential for optimal care in the elderly patient with transthyretin cardiac amyloidosis.

Entities:  

Keywords:  Cardiac Magnetic Resonance (CMR); Echocardiographic Strain; Technetium Pyrophosphate (99mTc-PYP); Transthyretin Cardiac Amyloidosis (ATTR-CA)

Year:  2017        PMID: 29057029      PMCID: PMC5648026          DOI: 10.1007/s12170-017-0541-x

Source DB:  PubMed          Journal:  Curr Cardiovasc Risk Rep        ISSN: 1932-9520


  80 in total

1.  Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis.

Authors:  Dermot Phelan; Patrick Collier; Paaladinesh Thavendiranathan; Zoran B Popović; Mazen Hanna; Juan Carlos Plana; Thomas H Marwick; James D Thomas
Journal:  Heart       Date:  2012-08-03       Impact factor: 5.994

2.  Scanning for soft-tissue amyloid.

Authors:  R W Kula; W K Engel; B R Line
Journal:  Lancet       Date:  1977-01-08       Impact factor: 79.321

3.  Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy.

Authors:  Enrica Perugini; Pier Luigi Guidalotti; Fabrizio Salvi; Robin M T Cooke; Cinzia Pettinato; Letizia Riva; Ornella Leone; Mohsen Farsad; Paolo Ciliberti; Letizia Bacchi-Reggiani; Francesco Fallani; Angelo Branzi; Claudio Rapezzi
Journal:  J Am Coll Cardiol       Date:  2005-09-20       Impact factor: 24.094

4.  Cardiovascular magnetic resonance in cardiac amyloidosis.

Authors:  Alicia Maria Maceira; Jayshree Joshi; Sanjay Kumar Prasad; James Charles Moon; Enrica Perugini; Idris Harding; Mary Noelle Sheppard; Philip Alexander Poole-Wilson; Philip Nigel Hawkins; Dudley John Pennell
Journal:  Circulation       Date:  2005-01-03       Impact factor: 29.690

5.  Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis.

Authors:  Imran S Syed; James F Glockner; Dali Feng; Philip A Araoz; Matthew W Martinez; William D Edwards; Morie A Gertz; Angela Dispenzieri; Jae K Oh; Diego Bellavia; A Jamil Tajik; Martha Grogan
Journal:  JACC Cardiovasc Imaging       Date:  2010-02

Review 6.  Prognostic Value of Late Gadolinium Enhancement CMR in Systemic Amyloidosis.

Authors:  Sameer Raina; Shelly Y Lensing; Ramez S Nairooz; Naga Venkata K Pothineni; Abdul Hakeem; Sabha Bhatti; Tarun Pandey
Journal:  JACC Cardiovasc Imaging       Date:  2016-08-24

7.  Does the etiology of cardiac amyloidosis determine the myocardial uptake of [18F]-NaF PET/CT?

Authors:  Christian Gagliardi; Elena Tabacchi; Rachele Bonfiglioli; Stefania Diodato; Cristina Nanni; Pierluigi Guidalotti; Massimiliano Lorenzini; Filippo Lodi; Agnese Milandri; Claudio Rapezzi; Stefano Fanti
Journal:  J Nucl Cardiol       Date:  2016-03-14       Impact factor: 5.952

8.  18F-Florbetapir Binds Specifically to Myocardial Light Chain and Transthyretin Amyloid Deposits: Autoradiography Study.

Authors:  Mi-Ae Park; Robert F Padera; Anthony Belanger; Shipra Dubey; David H Hwang; Vikas Veeranna; Rodney H Falk; Marcelo F Di Carli; Sharmila Dorbala
Journal:  Circ Cardiovasc Imaging       Date:  2015-08       Impact factor: 7.792

Review 9.  Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis.

Authors:  Teresa Coelho; Giampaolo Merlini; Christine E Bulawa; James A Fleming; Daniel P Judge; Jeffery W Kelly; Mathew S Maurer; Violaine Planté-Bordeneuve; Richard Labaudinière; Rajiv Mundayat; Steve Riley; Ilise Lombardo; Pedro Huertas
Journal:  Neurol Ther       Date:  2016-02-19

10.  A Routine PET/CT Protocol with Streamlined Calculations for Assessing Cardiac Amyloidosis Using (18)F-Florbetapir.

Authors:  Dustin R Osborne; Shelley N Acuff; Alan Stuckey; Jonathan S Wall
Journal:  Front Cardiovasc Med       Date:  2015-05-08
View more
  2 in total

1.  3D myocardial deformation analysis from cine MRI as a marker of amyloid protein burden in cardiac amyloidosis: validation versus T1 mapping.

Authors:  Na'ama Avitzur; Alessandro Satriano; Muhammad Afzal; Mariam Narous; Yoko Mikami; Reis Hansen; Gary Dobko; Jacqueline Flewitt; Carmen P Lydell; Andrew G Howarth; Kelvin Chow; Nowell M Fine; James A White
Journal:  Int J Cardiovasc Imaging       Date:  2018-07-16       Impact factor: 2.357

Review 2.  The quintessential form of diastolic heart failure in older adults: Wild type transthyretin cardiac amyloidosis.

Authors:  Elissa Driggin; Mathew S Maurer
Journal:  Clin Cardiol       Date:  2019-12-11       Impact factor: 2.882

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.